Atrasentan

Potent and selective endothelin a receptor (ET_A) antagonist， potential to attenuate hallmark characteristics of IgAN, including mesangial cell activation, proteinuria and kidney inflammation and fibrosis (Hit 4).

Demonstrated clinically significant reductions in proteinuria and risk of ESKD in a study of over 5300 patients with diabetic kidney disease (DKD), represents a potential therapy to reduce proteinuria and preserve kidney function in patients with IgAN.

• ●AFFINITY, global phase II study IgAN cohort interim data showed Atrasentan provides clinically meaningful proteinuria reduction in patients with IgAN receiving optimized SOC, demonstrated 38.0% proteinuria reduction at six weeks of treatment, 49.9% proteinuria reduction at 12 weeks of treatment and 58.5% reduction at 24 weeks of treatment.
• ●Phase III primary data readout in IgAN expected in 2023.